- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- MEDI4736
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 28
- States / cities
- Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 4,663
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Fountain Valley, California • Los Angeles, California + 22 more
- Conditions
- Laryngeal Diseases
- Interventions
- Amitriptyline, Placebo
- Drug · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
- Interventions
- ALVR106, Placebo
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- 17 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia, Dyspnea, Oxygen Inhalation Therapy
- Interventions
- Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 30 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Laboratory Biomarker Analysis, Vismodegib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Salt Lake City, Utah
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- Darlifarnib, Cabozantinib, Adagrasib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin, docetaxel
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 130
- States / cities
- Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Interventions
- Ubamatamab, Marlotamig, Sarilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 13 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 89
- States / cities
- Little Rock, Alaska • Hot Springs, Arkansas • Chula Vista, California + 69 more
- Conditions
- Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
- Interventions
- AirSense™ 10 AutoSet, Standard Medical Therapy
- Device · Other
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Respiration Failure, Cardio Vascular Disease, Cardiogenic Pulmonary Oedema, Critical Illness, Mechanical Ventilation, Cardiogenic Shock, Cardiopulmonary
- Interventions
- Volume Controlled Mode, Pressure Controlled Mode
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Respiratory Infections (ARIs)
- Interventions
- Clinical Decision Support: Accountable Justification, Audit and Feedback: Peer Comparison, CDS Order Sets: Suggested Alternatives
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neoplasm Metastasis, Brain Neoplasms
- Interventions
- Motexafin gadolinium
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- provider support tools plus spirometer
- Other
- Lead sponsor
- Memorial Hospital of Rhode Island
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 3,593 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Pawtucket, Rhode Island
- Conditions
- Lung Cancer, Head and Neck Cancer
- Interventions
- High Intensity Counseling + Long Acting NRT + PRN NRT, High Intensity Counseling + bupropion + PRN NRT, High Intensity Counseling + varenicline + PRN NRT, High Intensity Counseling + Long Acting NRT, High Intensity Counseling + bupropion, High Intensity Counseling + varenicline, Low Intensity Counseling + Long Acting NRT + PRN NRT, Low Intensity Counseling + bupropion + PRN NRT, Low Intensity Counseling + varenicline + PRN NRT, Low Intensity Counseling + Long Acting NRT, Low Intensity Counseling + bupropion, Low Intensity Counseling + varenicline
- Drug
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 10
- States / cities
- Ashland, Kentucky • Elizabethtown, Kentucky • Hazard, Kentucky + 5 more
- Conditions
- Lung Cancer, Non-Hodgkin's Lymphoma
- Interventions
- PET/CT scan
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Squamous Cell Carcinoma, Non-Small-Cell Lung
- Interventions
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Interventions
- Durvalumab, Sirolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- QGE031, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 27
- States / cities
- Fresno, California • Glendale, California • Orange, California + 21 more
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- CPT-Text, Culturally Informed Trauma Treatment (CITT), Retention Incentive, Reminder as Usual
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Palo Alto, California • New York, New York • San Antonio, Texas
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, celecoxib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois